Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Bio Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Kabushiki Kaisha

Masami Okabe

Motoo Yamasaki

Makoto Morimoto

Kazuo Yamaguchi

Moriyuki Sato

Seiga Itoh

Yoshiharu Yokoo

Hiromasa Miyaji

Tetsuro Kuga

Yoshinori Komatsu

Hajime Yoshida

Shiro Akinaga

Chikara Murakata

Yutaka Saito

Yutaka Saitoh

Tatsuya Tamaoki

Yukimasa Shiotsu

Takako Shiraki

Ken Kobayashi

Hirofumi Nakano

Hiromitsu Saito

Toshiyuki Suzawa

Fumihiko Kanai

Kumiko Maruyama

Toshimitsu Takiguchi

Junichi Watanabe

Takeshi Takahashi

Nobuo Hanai

Masaji Kasai

Akiko Furuya

Tadashi Ashizawa

Katsushige Gomi

Keiichi Takahashi

Mitsunobu Hara

Soichiro Sato

Akira Mihara

Shigeo Katsumata

Masami Kaneko

Kazuhito Akasaka

Junji Kanazawa

Uichiro Kimura

Shun-Ichi Ikeda

Kimihito Sasaki

Etsuko Nukui

Toshiaki Kamei

Toshiaki Saeki

Yoji Ikuina

The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet production promoter comprising said polypeptide, a method for treating a patient with decreased platelet counts comprising administering an effective amount of said polypeptide to the patient, the use of said polypeptide for the production of pharmaceutical compositions which are useful for the treatment of the patient with decreased platelet counts, and the compositions for treating the patient with decreased platelet counts, which comprises an effective dose of said polypeptide in a pharmaceutically acceptable dosage form with a pharmaceutical acceptable carrier.

Platelet production promoting agent

Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.

G-CSF conjugate

Method of producing a polypeptide having human granulocyte colony

The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.

Propenone derivatives

An anti-ribonucleotide reductase (RNR) R2 subunit monoclonal antibody KM1054, KM1056 or KM1060, which belongs to the IgG2a subclass, reacts with R2 subunit of RNR, and inhibits RNR activity, is disclosed. It is effective for immunologically detecting RNR and for immunologically detecting the presence of human cancer cells.

Anti-ribonucleotide reductase R2 subunit monoclonal antibody

Polypeptide derivatives of human granulocyte colony stimulating factor

DNA encoding human granulocyte colony stimulating factor plasmids and

The present invention relates to therapeutic agents for thrombocytopenia which contain an indolocarbazole derivative represented by the formula (I) given below or a pharmaceutically acceptable salt thereof as an active ingredient, and to novel indolocarbazole derivatives. ##STR1##

Indolocarbazole derivatives and therapeutic method for stimulating

The present invention provides a method of treating thrombocytopenia, which comprises administering to a patient suffering from thrombocytopenia, an effective amount of an indolocarbazole derivative represented by formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group or a tetrahydropyranyl group; R.sup.2A and R.sup.3A, which may be the same or different, each represent a hydrogen atom, a substituted or unsubstituted lower alkyl group, a lower alkenyl group, a substituted or unsubstituted aralkyl group or a monosaccharide residue where a hydroxyl group at the anomer position is removed; R.sup.4A and R.sup.5A, which may be the same or different, each represent a hydrogen atom, a formyl group, a hydroxyl group or a halogen atom; W.sup.A1 and W.sup.A2 represent hydrogen atoms or are combined together to form an oxygen atom; and X.sup.A1 and X.sup.A2 represents two hydrogen atoms or are combined together to form a single bond, provided that when X.sup.A forms a single bond, then R.sup.1, R.sup.2A, R.sup.3A, R.sup.4A, R.sup.5A, and W.sup.A do not simultaneously represent a hydrogen atom, or a pharmaceutically acceptable salt.

Therapeutic agent for thrombocytopenia and indolocarbazole derivatives

Disclosed is an indolocarbazole derivative represented by the following formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## [wherein R.sup.1 represents substituted or unsubstituted lower alkyl, R.sup.2 represents hydrogen, substituted or unsubstituted lower alkyl, R.sup.3 and R.sup.4 are the same or different, and represent hydrogen, nitro, NR.sup.5 R.sup.6, OR.sup.9, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, or CH.dbd.NNR.sup.10 R.sup.11, W represents two hydrogen atoms or oxygen, and Me represents methyl, provided that when R.sup.1 is unsubstituted lower alkyl, R.sup.3 and R.sup.4 are not simultaneously hydrogen.

Indolocarbazole derivatives that stimulate platelet production

Epoxycyclohexenedione derivatives

Disclosed is a process for producing a staurosporine derivative represented by Formula (I): Q is defined as in specification: ##STR1## The staurosporine derivative (I-1) possesses selective protein kinase C-inhibitory and cell growth-inhibiting activities, and platelet-increasing activity.

Process for producing staurosporine derivatives

Growing community of inventors

Shizuoka, Japan

Masami Okabe